Andrew Cheng, MD, PhD

Our Team


Andrew Cheng, MD, PhD
President & CEO

Andrew Cheng was formerly the chief medical officer and executive vice president at Gilead Sciences. During his nearly 20 year tenure, he was responsible for the clinical development for the HIV program resulting in 11 FDA/EMA approved products. His past roles also included medical affairs and the creation of the development operations department (regulatory affairs, clinical operations, pharmacovigilance, project management, clinical pharmacology and biometrics) which covered clinical development support in multiple therapeutic areas including oncology, inflammation, respiratory, cardiovascular, HIV and liver diseases. He sits on the board of directors for Syntimmune, a clinical stage biotechnology company developing antibody therapeutics targeting FcRn and for the non-profit global virus network focused on virology research, education & advocacy.

Dr. Cheng was board certified in internal medicine and completed his postgraduate training at the University of California, Los Angeles. He received his M.D. and Ph.D. in cellular and molecular biology from Columbia University, where he received a NIH Medical Scientist Training Program fellowship.